drugset / Trial / NCT04233112

Melatonin and Osteogenic Loading on Osteopenia

NCT04233112

Phase 0 Active not recruiting 40 enrolled Duquesne University OsteoStrong · collab
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study will be assessing the efficacy of melatonin and/or osteogenic loading on modulating bone health in an osteopenic population.

Timeline

Start
2020-05-26
Primary completion
2024-12-31
Completion
2025-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 5 mg

Indications

No indication recorded.